Barclays Reiterates Overweight Rating on Radient Pharmaceuticals (RPC)

April 8, 2026 3:57 AM

Barclays reiterated an Overweight rating and $11.00 price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found